Drugs / Azelastine Hydrochl./Fluticasone Prop.
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03599791 | Jun 2018 → Sep 2019 | allergic rhinitis | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azelastine Hydrochl./Fluticasone Prop. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03599791 ↗ |
| Known as | MP-AzeFlu | “A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal...” PMID 37580498 ↗ Aug 2023 |
| Route | Intranasal | “Dymista Nasal spray suspension” NCT03599791 ↗ |